FCA remits pricing decision on ALEXION'S SOLIRIS to PMPRB | Smart & Biggar - JDSupra

Retrieved on: 2021-08-25 13:41:15

Tags for this article:

Health care

Life Sciences

Eculizumab

Immunosuppressants

Drugs

Alexion Pharmaceuticals

Patented Medicine Prices Review Board

Pricing

Soliris

Alexion Pharmaceuticals Inc.

Click the tags to see associated articles and topics

FCA remits pricing decision on ALEXION'S SOLIRIS to PMPRB | Smart & Biggar - JDSupra. View article details on HISWAI: https://www.jdsupra.com/legalnews/fca-remits-pricing-decision-on-alexion-6441213/

Excerpt

In September 2017, the Patented Medicine Prices Review Board (PMPRB or Board) decided (see article here) that Alexion's SOLIRIS (eculizumab) was sold at an ...

Article found on: www.jdsupra.com

View Original Article